Avidity Biosciences, Inc. - COMMON STOCK (RNA)

Historical Holders from Q2 2020 to Q3 2025

Symbol
RNA on Nasdaq
CUSIP
05370A108
Type / Class
Equity / COMMON STOCK
Shares outstanding
138M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
161M
Holdings value
$7.01B
% of all portfolios
0.011%
Grand Portfolio weight change
+0.002%
Number of holders
260
Number of buys
184
Number of sells
-70
Average Value change %
+0%
Average buys %
+0.005%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Avidity Biosciences, Inc. - COMMON STOCK (RNA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10.7% +6% $633M $104M 14.5M +19.7% JANUS HENDERSON GROUP PLC Sep 30, 2025
VANGUARD GROUP INC 9.57% $576M 13.2M The Vanguard Group Sep 30, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $426M 9.79M T. Rowe Price Associates, Inc. Sep 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 8.1% $248M 9.68M Wellington Management Group LLP Mar 31, 2025
RA CAPITAL MANAGEMENT, L.P. 5.9% $376M 8.64M RA Capital Management, L.P. Sep 30, 2025
BlackRock, Inc. 6.4% -13.8% $376M -$17.9M 8.63M -4.55% BlackRock, Inc. Sep 30, 2025
RTW INVESTMENTS, LP 3.1% $204M 4.69M RTW Investments, LP Oct 27, 2025
FMR LLC 2.1% -86% $129M -$810M 2.96M -86.3% FMR LLC Oct 31, 2025

Institutional Holders of Avidity Biosciences, Inc. - COMMON STOCK (RNA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 161M $7.01B +$1.15B $43.57 260
2025 Q2 136M $3.86B +$69.7M $28.40 205
2025 Q1 133M $3.96B +$178M $29.52 218
2024 Q4 128M $3.71B -$47.5M $29.08 232
2024 Q3 125M $5.75B +$525M $45.93 239
2024 Q2 112M $4.57B +$938M $40.85 191
2024 Q1 89.2M $2.28B +$379M $25.52 155
2023 Q4 99.9K $904K -$576K $9.05 2
2023 Q3 5.22M $33.3M -$4.35M $6.38 14
2023 Q2 82.4M $914M +$45.8M $11.09 138
2023 Q1 75.9M $1.16B +$45.1M $15.35 136
2022 Q4 71.6M $1.59B +$415M $22.19 145
2022 Q3 53.4M $872M -$46.9M $16.33 116
2022 Q2 51.9M $754M +$37.2M $14.53 100
2022 Q1 46.9M $866M +$27.2M $18.47 93
2021 Q4 45.4M $1.08B +$3.61M $23.77 101
2021 Q3 44.4M $1.09B +$240M $24.63 109
2021 Q2 34.5M $852M +$17.4M $24.71 92
2021 Q1 33.9M $739M +$60.8M $21.81 97
2020 Q4 30.8M $787M +$74.4M $25.52 81
2020 Q3 27M $755M +$43.8M $28.15 66
2020 Q2 25.5M $702M +$701M $28.26 52